PrEP implementation research in Africa: What is new?

Journal of the International AIDS Society

Volumn 19, Issue , 2016, Pages

  Cowan, Frances M ^a,b   Delany Moretlwe, Sinead ^c   Sanders, Eduard J ^d,e   Mugo, Nelly R ^f,g,h   Guedou, Fernand A ⁱ   Alary, Michel ^j   Behanzin, Luc ⁱ   Mugurungi, Owen ^k   Bekker, Linda Gail ^l  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b CENTRE FOR SEXUAL HEALTH AND HIV AIDS RESEARCH   (Zimbabwe)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f Center for Clinical Research   (Kenya)

^g UNIVERSITY OF WASHINGTON   (United States)

^h PARTNERS IN HEALTH   (United States)

ⁱ Centre de santé communal de Cotonou 1   (Benin)

^j Université Laval   (Canada)

^k MINISTRY OF HEALTH AND CHILD CARE   (Zimbabwe)

^l UNIVERSITY OF CAPE TOWN   (South Africa)

more..

Author keywords

Adherence; Africa; Empowerment; HIV AIDS; Implementation; Key populations; Pre exposure prophylaxis; Prevention

Indexed keywords

AFRICA; AFRICA SOUTH OF THE SAHARA; COST EFFECTIVENESS ANALYSIS; DRUG USE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALE TO FEMALE TRANSGENDER; MEN WHO HAVE SEX WITH MEN; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; SEX WORKER; ADOLESCENT; ADULT; FEMALE; HEALTH SERVICE; HIV INFECTIONS; MALE; MASS SCREENING; YOUNG ADULT;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; AFRICA; ANTI-HIV AGENTS; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HIV INFECTIONS; HUMANS; MALE; MASS SCREENING; PRE-EXPOSURE PROPHYLAXIS; SEX WORKERS; YOUNG ADULT;

EID: 84995438658     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.19.7.21101     Document Type: Review

References (77)

1. HIV/AIDS JUNPo. Global AIDS update 2016. Geneva: Joint United Nations Programme on HIV/AIDS; 2016.
2. UNAIDS. 90-90-90 an ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS; 2014. Contract No.: UNAIDS/JC2684.
3. UNAIDS. Invest in HIV prevention. Geneva: Joint United Nations Programme on HIV/AIDS; 2015. Contract No.: UNAIDS/JC2791E.
4. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: WHO; 2015.
5. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV pre-exposure prophylaxis (PrEP) for all populations: A systematic review and meta-Analysis. AIDS. 2016;30(12): 1973-83. doi:http://dx.doi.org/10.1097/qad.0000000000001145.
6. Bekker L, Rebe R, Venter F, Maartens G, Moorhouse M, Conradie F, et al. Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection. South Afr J HIV Med. 2016;17: 11. doi:http://dx.doi.org/10.4102/hivmed.v17i1.455.
7. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: A aystematic review of cost-effectiveness modelling studies. PLoS Med. 2013; 10(3):e1001401. doi:http://dx.doi.org/10.1371/journal.pmed.1001401.
8. HIV Section U. Consultation on clinical, ethical and operational considerations for the implementation of oral pre-exposure prophylaxis (PrEP) in sexually active older adolescents (15-19) at high risk of HIV infection Meeting Report; Vancouver, Canada; 2015 July 17-18; New York: UNICEF; 2015.
9. UNAIDS. UNAIDS 2016-21 strategy: on the Fast-Track to end AIDS. Geneva: UNAIDS; 2015.
10. Baeten J, Heffron R, Kidoguchi L, Mugo N, Katabira E, Bukusi E, et al. Near elimination of HIV transmission in a demonstration project of PrEP and ART. Conference on Retroviruses and Opportunistic Infections. 23-26 Feb 2016; Seattle, WA; 2015.
11. Cowan FM, Mtetwa S, Davey C, Fearon E, Dirawo J, Wong-Gruenwald R, et al. Engagement with HIV prevention treatment and care among female sex workers in Zimbabwe: A respondent driven sampling survey. PLoS One. 2013;8(10):e77080. doi:http://dx.doi.org/10.1371/journal.pone.0077080.
12. Maman S, Mbwambo J, Hogan NM, Kilonzo GP, Sweat M.Women's barriers to HIV-1 testing and disclosure: challenges for HIV-1 voluntary counselling and testing. AIDS Care. 2001;13(5):595-603. doi:http://dx.doi.org/10.1080/09540120120063223.
13. Mshana GH, Wamoyi J, Busza J, Zaba B, Changalucha J, Kaluvya S, et al. Barriers to accessing antiretroviral therapy in Kisesa, Tanzania: A qualitative study of early rural referrals to the national program. AIDS Patient Care STDS. 2006;20(9):649-57. doi:http://dx.doi.org/10.1089/apc.2006.20.649.
14. Munoz J, Adedimeji AA, Alawode O. 'The bring AIDS to us and say we give it to them': socio-structural context of female sex workers' vulnerabiity to HIV infection in Ibadan, Nigeria. SAHARA J. 2010;7(2):52-61. doi:http://dx.doi.org/10.1080/17290376.2010.9724957.
15. Mtetwa S, Busza J, Chidiya S, Mungofa S, Cowan F. "You are wasting our drugs": health service barriers to HIV treatment for sex workers in Zimbabwe. BMC Public Health. 2013;13:698. doi:http://dx.doi.org/10.1186/1471-2458-13-698.
16. WHO. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2014.
17. Bekker L-G, Johnson L, Cowan F, Overs C, Besada D, Hillier S, et al. Combination HIV prevention for female sex workers: What is the evidence? Lancet. 2015;385(9962):72-87. doi:http://dx.doi.org/10.1016/S0140-6736(14)60974-0.
18. Chersich MF, Luchters S, Ntaganira I, Gerbase A, Lo YR, Scorgie F, et al. Priority interventions to reduce HIV transmission in sex work settings in sub- Saharan Africa and delivery of these services. J Int AIDS Soc. 2013;16:17980, doi:http://dx.doi.org/10.7448/IAS.16.1.17980.
19. Kerrigan D, Kennedy CE, Morgan-Thomas R, Reza-Paul S, Mwangi P, Win KT, et al. A community empowerment approach to the HIV response among sex workers: Effectiveness, challenges, and considerations for implementation and scale-up. Lancet. 2015;385(9963):172-85. doi:http://dx.doi.org/10.1016/s0140-6736(14)60973-9.
20. Decker MR, Crago AL, Chu SK, Sherman SG, Seshu MS, Buthelezi K, et al. Human rights violations against sex workers: burden and effect on HIV. Lancet. 2015;385(9963):186-99. doi:http://dx.doi.org/10.1016/s0140-6736(14)60800-x.
21. Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, Bangsberg D, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One. 2012;7(4):e33103. doi:http://dx.doi.org/10.1371/journal.pone.0033103.
22. Hargreaves JR, Fearon E, Davey C, Phillips A, Cambiano V, Cowan FM. Statistical design and analysis plan for an impact evaluation of an HIV treatment and prevention intervention for female sex workers in Zimbabwe: A study protocol for a cluster randomised controlled trial. Trials. 2016;17:6. doi:http://dx.doi.org/10.1186/s13063-015-1095-1.
23. Sex workers to get HIV treatment, ARVs: South Africa has become one of the first countries in the world to prevent and treat HIV among sex workers [Internet]. [cited 2016 Mar 15]. Available from: http://www.health24.com/Medical/HIV-AIDS/News/sa-rolls-out-hiv-Treatment-Arvs-To-sex-workers-20160314?isapp-True.
24. Chomont N, Grésenguet G, Lévy M, Hocini H, Becquart P, Matta M, et al. Detection of Y chromosome DNA as evidence of semen in cervicovaginal secretions of sexually active women. Clin Diagn Lab Immunol. 2001;8(5):955-8. doi:http://dx.doi.org/10.1128/cdli.8.5.955-958.2001.
25. Minnis AM, Steiner MJ, Gallo MF, Warner L, Hobbs MM, van der Straten A, et al. Biomarker validation of reports of recent sexual activity: Results of a randomized controlled study in Zimbabwe. Am J Epidemiol. 2009;170(7): 918-24. doi:http://dx.doi.org/10.1093/aje/kwp219.
26. Cowan FM, Davey C, Napierala MS, Mushati P, Mtetwa S, Chiyaka T, et al. Estimation of the HIV care cascade for female sex workers in Zimbabwe: baseline results of the SAPPH-Ire trial. 20th International AIDS Conference. 20-25 July. Melbourne, Australia; 2014.
27. Tanser F, de Oliveira T, Maheu-Giroux M, Bärnighausen T. Concentrated HIV sub-epidemics in generalized epidemic settings. Curr Opin HIV AIDS. 2014;9(2):115-25. doi:http://dx.doi.org/10.1097/coh.0000000000000034.
28. McKinnon LR, Gakii G, Juno JA, Izulla P, Munyao J, Ireri N, et al. High HIV risk in a cohort of male sex workers from Nairobi, Kenya. Sex Transm Infect. 2014;90(3):237-42. doi:http://dx.doi.org/10.1136/sextrans-2013-051310.
29. Price MA, Rida W, Mwangome M, Mutua G, Middelkoop K, Roux S, et al. Identifying at-risk populations in Kenya and South Africa: HIV incidence in cohorts of men who report sex with men, sex workers, and youth. J Acquir Immune Defic Syndr. 2012;59(2):185-93. doi:http://dx.doi.org/10.1097/QAI.0b013e31823d8693.
30. Sanders EJ, Okuku HS, Smith AD, Mwangome M, Wahome E, Fegan G, et al. High HIV-1 incidence, correlates of HIV-1 acquisition, and high viral loads following seroconversion among MSM. AIDS. 2013;27(3):437-46. doi:http://dx.doi.org/10.1097/QAD.0b013e32835b0f81.
31. Semugoma P, Nemande S, Baral SD. The irony of homophobia in Africa. Lancet. 2012;380(9839):312-14. doi:http://dx.doi.org/10.1016/s0140-6736(12)60901-5.
32. Beyrer C, Sullivan PS, Sanchez J, Dowdy D, Altman D, Trapence G, et al. A call to action for comprehensive HIV services for men who have sex with men. Lancet. 2012;380(9839):424-38. doi:http://dx.doi.org/10.1016/s0140-6736(12)61022-8.
33. Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17(6):2162-72. doi:http://dx.doi.org/10.1007/s10461-012-0317-8.
34. Hegdahl HK, Fylkesnes KM, Sandoy IF. Sex differences in HIV prevalence persist over time: Evidence from 18 countries in Sub-Saharan Africa. PLoS One. 2016;11(2):e0148502. doi:http://dx.doi.org/10.1371/journal.pone.0148502.
35. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-22. doi:http://dx.doi.org/10.1056/NEJMoa1202614.
36. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509-18. doi:http://dx.doi.org/10.1056/NEJMoa1402269.
37. Nachega J, Hislop M, Nguyen M, Dowdy D, Chaisson RE, Regensburg L, et al. Antiretroviral treatment adherence, virologic and immunologic outcomes in adolescents compared with adults in Southern Africa. J Acquir Immune Defic Syndr. 2009;51(1):65-71. doi:http://dx.doi.org/10.1097/QAI.0b013e318199072e.
38. Bekker L, Grant R, Hughes J, Roux S. HPTN 067/ADAPT Cape Town: A comparison of daily and nondaily PrEP dosing in African women. 2016 Feb 23-26; Seattle, WA: CROI; 2015.
39. Becker S, Gray R. Source of new infections in generalised HIV epidemics. Lancet. 2008;372(9646):1299-300; author reply 300-1. doi:http://dx.doi.org/10.1016/S0140-6736(08)61546-9.
40. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2010 Report on the Global AIDS Epidemic. Geneva: UNAIDS; 2010.
41. Pruden HJ, Watts CH, Vickerman P, Bobrova N, Heise L, Ogungbemi M, et al. Can the UNAIDS modes of transmission model be improved? A comparison of the original and revised model projections using data from a setting in west Africa. AIDS. 2013;27:2623-35. doi:http://dx.doi.org/10.1097/01.aids.0000432476.22616.2f.
42. Dunkle KL, Stephenson R, Karita E, Chomba E, Kayitenkore K, Vwalika C, et al. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: An analysis of survey and clinical data. Lancet. 2008;371(9631):2183-91. doi:http://dx.doi.org/10.1016/S0140-6736(08)60953-8.
43. UNAIDS. Addressing societal causes of HIV risk and vulnerability. 2008 Report on the Global AIDS Epidemic. Geneva: UNAIDS; 2008. p. 64-93.
44. Chemaitelly H, Shelton J, Hallett T, Abu-Raddad L. Only a fraction of new HIV infections occur within identifiable stable discordant couples in sub- Saharan Africa. AIDS (London, England). 2013;27(2):251-60. doi:http://dx.doi.org/10.1097/QAD.0b013e32835ad459.
45. WHO HIV/AIDS Programme. Guidance on couples HIV testing and counselling - including antiretroviral therapy for treatment and prevention in serodiscordant couples: Recommendations for a public health approach. Geneva: World Health Organization; 2012.
46. World Health Organization. Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: Recommendations for use in the context of demonstration projects. Geneva: World Health Organization; 2013.
47. Matthews L, Baeten J, Celum C, Bangsberg D. Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS. 2010;24:1975-82. doi:http://dx.doi.org/10.1097/QAD.0b013e32833bedeb.
48. Ratmann O, van Sighem A, Bezemer D, Gavryushkina A, Jurriaans S, Wensing A, et al. Sources of HIV infection among men having sex with men and implications for prevention. Sci Transl Med. 2016;8(320):320-2. doi:http://dx.doi.org/10.1126/scitranslmed.aad1863.
49. Powers KA, Cohen MS. Acute HIV-1 infection in sub-Saharan Africa: A common occurrence overlooked. AIDS. 2014;28(9):1365-7. doi:http://dx.doi.org/10.1097/QAD.0000000000000277.
50. Rosenberg NE, Pilcher CD, Busch MP, Cohen MS. How can we better identify early HIV infections? Curr Opin HIV AIDS. 2015;10(1):61-8. doi:http://dx.doi.org/10.1097/COH.0000000000000121.
51. Sanders EJ, Wahome E, Powers KA, Werner L, Fegan G, Lavreys L, et al. Targeted screening of at-risk adults for acute HIV-1 infection in sub-Saharan Africa. AIDS. 2015;29(Suppl 3):S221-S30. doi: http://dx.doi.org/10.1097/QAD. 0000000000000924.
52. Hargreaves J, Delany S, Hallett T, Johnson S, Krishnaratne S, Hensen B, et al. Strengthening HIV prevention with available tools: Translating theory into programme design. HIV Lancet. 2016;3:e318-e22. doi:http://dx.doi.org/10.1016/S2352-3018(16)30063-7.
53. (NSWP) Gnoswp, Rights PHaH. HIV Australia publishes article by sex workers highlighting community concerns with broad implementation of PrEP 2015 [cited 2015 Sep 1]. Available from: http://www.nswp.org/news/hivaustralia-publishes-Article-sex-workers-highlighting-community-concerns-broad.
54. Overs C, Hawkins K. Examining the implications of PrEP as HIV prevention for sex workers. Brighton: Institute of Development Studies; 2016.
55. van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women's experiences with oral and vaginal pre-exposure prophylaxis: The VOICE-C qualitative study in Johannesburg, South Africa. PLoS One. 2014;9(2):e89118. doi:http://dx.doi.org/10.1371/journal.pone.0089118.
56. World Health Organization. Consolidated guidelines on HIV testing services: 5Cs: consent, confidentiality, counselling, correct results and Connection. Geneva: World Health Organization; 2015.
57. Krakower DS, Mayer KH. The role of healthcare providers in the roll out of preexposure prophylaxis. Curr Opin HIV AIDS. 2016;11(1):41-8. doi:http://dx.doi.org/10.1097/coh.0000000000000206.
58. Mugo NR, Ngure K, Kiragu M, Irungu E, Kilonzo N. The preexposure prophylaxis revolution; from clinical trials to programmatic implementation. Curr Opin HIV AIDS. 2016;11(1):80-6. doi:http://dx.doi.org/10.1097/coh.0000000000000224.
59. Delany-Moretlwe S, Mullick S, Eakle R, Rees H. Planning for HIV preexposure prophylaxis introduction: lessons learned from contraception. Curr Opin HIV AIDS. 2016;11(1):87-93. doi:http://dx.doi.org/10.1097/coh.0000000000000221.
60. Mayer KH. NextGen HIV prevention: new possibilities and questions. Lancet. 387(10023):1036-8. doi:http://dx.doi.org/10.1016/S0140-6736(16)00655-3.
61. Balkus JE, Brown E, Palanee T, Nair G, Gafoor Z, Zhang J, et al. An empiric HIV risk scoring tool to predict HIV-1 acquisition in African women. J Acquir Immune Defic Syndr. 2016;72(3):333-43. doi:http://dx.doi.org/10.1097/qai.0000000000000974.
62. Kahle EM, Hughes JP, Lingappa JR, John-Stewart G, Celum C, Nakku-Joloba E, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1- serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr. 2013;62(3):339-47. doi:http://dx.doi.org/10.1097/QAI.0b013e31827e622d.
63. Haberer JE. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Curr Opin HIV AIDS. 2016;11(1):10-17. doi:http://dx.doi.org/10.1097/coh.0000000000000220.
64. Haberer JE, Bangsberg DR, Baeten JM, Curran K, Koechlin F, Amico KR, et al. Defining success with HIV pre-exposure prophylaxis: A preventioneffective adherence paradigm. AIDS. 2015;29(11):1277-85. doi:http://dx.doi.org/10.1097/qad.0000000000000647.
65. Louissaint N, Cao Y, Skipper P, Liberman R, Tannenbaum S, Nimmagadda S, et al. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses. 2013;29:1443-50. doi:http://dx.doi.org/10.1089/aid.2013.0044.
66. Patterson K, Prince H, Kraft E, Jenkins A, Shaheen N, Rooney J, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3:112-4. doi:http://dx.doi.org/10.1126/scitranslmed.3003174.
67. Cottrell ML, Yang KH, Prince HMA, Sykes C, White N, Malone S, et al. A translational pharmacology approach to predicting HIV pre-exposure prophylaxis outcomes in men and women using tenofovir disoproxil fumarate 9emtricitabine. J Infect Dis. 2016; 214(1):55-64. doi:http://dx.doi.org/10.1093/infdis/jiw077.
68. Soobratty MR, Whitfield R, Subramaniam K, Grove G, Carver A, O'Donovan GV, et al. Point-of-care urine test for assessing adherence to isoniazid treatment for tuberculosis. Eur Respir J. 2014;43(5):1519-22. doi:http://dx.doi.org/10.1183/09031936.00132613.
69. Herron AJ, Mariani JJ, Pavlicova M, Parrinello CM, Bold KW, Levin FR, et al. Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement. Drug Alcohol Depend. 2013;128(1-2):77-82. doi:http://dx.doi.org/10.1016/j.drugalcdep.2012.08.007.
70. DePriest AZ, Black DL, Robert TA. Immunoassay in healthcare testing applications. J Opioid Manage. 2015;11(1):13-25. doi:http://dx.doi.org/10.5055/jom.2015.0248.
71. Safren SA, O'Cleirigh C, Tan JY, Raminani SR, Reilly L, Otto MW, et al. A randomized trial of cognitive behavioural therapy for adherence and depression in HIV infected individuals. Health Psychol. 2009;28:1-10. doi:http://dx.doi.org/10.1037/a0012715.
72. Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, de Walque D, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: A randomized controlled trial of text message reminders. AIDS. 2011;25(6):825-34. doi:http://dx.doi.org/10.1097/QAD.0b013e32834380c1.
73. Simoni J, Amico K, Smith L, Nelson K. Antiretroviral adherence interventions: Translating research findings to the real world clinic. Curr HIV/AIDS Rep. 2010;7(1):44-51. doi:http://dx.doi.org/10.1007/s11904-009-0037-5.
74. Rueda S, Park-Wylie L, Bayoumi A, Tynan A-M, Antoniou T, Rourke S, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database of Syst Rev. 2006;(3):CD001442. doi:http://dx.doi.org/10.1002/14651858.CD001442.pub2.
75. Govindasamy D, Meghij J, Negussi EK, Baggaley RC, Ford N, Kranzer K. Interventions to improve or facilitate linkage to or retention in pre-ART (HIV) care and initiation of ART in low-And middle-income settings -A systematic review. J Int AIDS Soc. 2014;17(1):19032. doi:http://dx.doi.org/10.7448/IAS.17.1.19032.
76. Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, Ellman T, et al. Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature. 2015;528(7580):S68-S76. doi:http://dx.doi.org/10.1038/nature16046.
77. UNAIDS, Frontières Ms. Community based antiretroviral therapy delivery: Experiences of Médecins sans Frontiè res. Geneva: UNAIDS; 2015.